In a report released on March 27, David Roman from Goldman Sachs maintained a Hold rating on Healthequity (HQY – Research Report), with a price ...

HealthEquity (NASDAQ:HQY – Free Report) had its price objective trimmed by The Goldman Sachs Group from $107.00 to $94.00 in a report published on Thursday morning,Benzinga reports. The firm currently ...

HealthEquity (NASDAQ:HQY – Get Free Report) was upgraded by analysts at Raymond James from an “outperform” rating to a “strong-buy” rating in a note issued to investors on Tuesday, MarketBeat.com ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: ...

Raymond James analyst Gregory Peters upgraded Healthequity (HQY – Research Report) to a Buy yesterday and set a price target of $115.00. The ...

On a per-share basis, that figure was $0.69. This meant a mixed quarter for HealthEquity. While it beat the average analyst estimate of $305.8 million for revenue, it fell short of the consensus $ ...

Shares of HealthEquity, Inc. fell more than 17% on Wednesday, registering the worst drop since December 2021, after the health-savings account custodian projected near-term earnings that fell below ...

In this article, we are going to take a look at where HealthEquity Inc. (NASDAQ:HQY) stands against other Wednesday’s worst performers. Shares on Wall Street bounced back from a bloodbath ...

Understanding Analyst Ratings: A Comprehensive Breakdown The standing of HealthEquity among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below ...

Shares of HealthEquity (NASDAQ:HQY) fell ~20% on Wednesday, marking its biggest one-day decline in more than three years, ...

HealthEquity, Inc. (NASDAQ ... At these levels, we err on selling but are giving this a neutral rating overall given where it is currently priced. When stocks run like this one had, we like ...